resiquimod   Click here for help

GtoPdb Ligand ID: 5051

Synonyms: R-848 | R848
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Resiquimod (R-848) is a more potent derivative of the imidazoquinoline compound imiquimod [1]. It acts as a TLR7 agonist.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

resiquimod is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 86.19
Molecular weight 314.17
XLogP 1.94
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCOCc1nc2c(n1CC(O)(C)C)c1ccccc1nc2N
Isomeric SMILES CCOCc1nc2c(n1CC(O)(C)C)c1ccccc1nc2N
InChI InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
InChI Key BXNMTOQRYBFHNZ-UHFFFAOYSA-N
References
1. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.
Nat Immunol, 3 (2): 196-200. [PMID:11812998]
2. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. (2002)
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.
Nat Immunol, 3 (6): 499. [PMID:12032557]
3. Larson P, Kucaba TA, Xiong Z, Olin M, Griffith TS, Ferguson DM. (2017)
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
ACS Med Chem Lett, 8 (11): 1148-1152. [PMID:29152046]
4. Stockfleth E, Hofbauer GFL, Reinhold U, Popp G, Hengge UR, Szeimies RM, Brüning H, Anliker M, Hunger T, Dummer R et al.. (2019)
Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial.
Br J Dermatol, 180 (2): 297-305. [PMID:30171698]